These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22691797)

  • 1. On-column ligand exchange for structure-based drug design: a case study with human 11β-hydroxysteroid dehydrogenase type 1.
    Qin W; Judge RA; Longenecker KL; Solomon LR; Harlan JE
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 May; 68(Pt 5):601-5. PubMed ID: 22691797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
    Yang H; Dou W; Lou J; Leng Y; Shen J
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of 11β-hydroxysteroid dehydrogenase type 1 and their use in drug discovery.
    Thomas MP; Potter BV
    Future Med Chem; 2011 Mar; 3(3):367-90. PubMed ID: 21446847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).
    Sun D; Wang Z; Di Y; Jaen JC; Labelle M; Ma J; Miao S; Sudom A; Tang L; Tomooka CS; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3513-6. PubMed ID: 18511278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
    Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
    J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
    Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
    J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening.
    Lagos CF; Vecchiola A; Allende F; Fuentes CA; Tichauer JE; Valdivia C; Solari S; Campino C; Tapia-Castillo A; Baudrand R; Villarroel P; Cifuentes M; Owen GI; Carvajal CA; Fardella CE
    Mol Cell Endocrinol; 2014 Mar; 384(1-2):71-82. PubMed ID: 24447464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
    Ye XY; Yoon D; Chen SY; Nayeem A; Golla R; Seethala R; Wang M; Harper T; Sleczka BG; Apedo A; Li YX; He B; Kirby M; Gordon DA; Robl JA
    Bioorg Med Chem Lett; 2014 Jan; 24(2):654-60. PubMed ID: 24360604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure based design of 11β-HSD1 inhibitors.
    Singh S; Tice C
    Curr Pharm Biotechnol; 2010 Nov; 11(7):779-91. PubMed ID: 20809895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model.
    Julian LD; Wang Z; Bostick T; Caille S; Choi R; DeGraffenreid M; Di Y; He X; Hungate RW; Jaen JC; Liu J; Monshouwer M; McMinn D; Rew Y; Sudom A; Sun D; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
    J Med Chem; 2008 Jul; 51(13):3953-60. PubMed ID: 18553955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Insights and Docking Analysis of Adamantane-Linked 1,2,4-Triazole Derivatives as Potential 11β-HSD1 Inhibitors.
    Osman DA; Macías MA; Al-Wahaibi LH; Al-Shaalan NH; Zondagh LS; Joubert J; Garcia-Granda S; El-Emam AA
    Molecules; 2021 Sep; 26(17):. PubMed ID: 34500764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Amino-N-adamantyl-3-methylbutanamide derivatives as 11β-hydroxysteroid dehydrogenase 1 inhibitor.
    Lee Y; Shin YJ; Ahn SK
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1421-5. PubMed ID: 24507919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model.
    Wan ZK; Chenail E; Xiang J; Li HQ; Ipek M; Bard J; Svenson K; Mansour TS; Xu X; Tian X; Suri V; Hahm S; Xing Y; Johnson CE; Li X; Qadri A; Panza D; Perreault M; Tobin JF; Saiah E
    J Med Chem; 2009 Sep; 52(17):5449-61. PubMed ID: 19673466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of 7-azaindole-pyrrolidine amides as inhibitors of 11β-hydroxysteroid dehydrogenase type I.
    Valeur E; Christmann-Franck S; Lepifre F; Carniato D; Cravo D; Charon C; Bozec S; Musil D; Hillertz P; Doare L; Schmidlin F; Lecomte M; Schultz M; Roche D
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5909-14. PubMed ID: 22901389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring N-acyl-4-azatetracyclo[5.3.2.0
    Leiva R; McBride A; Binnie M; Webster SP; Vázquez S
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic model.
    Fotsch C; Bartberger MD; Bercot EA; Chen M; Cupples R; Emery M; Fretland J; Guram A; Hale C; Han N; Hickman D; Hungate RW; Hayashi M; Komorowski R; Liu Q; Matsumoto G; St Jean DJ; Ursu S; Véniant M; Xu G; Ye Q; Yuan C; Zhang J; Zhang X; Tu H; Wang M
    J Med Chem; 2008 Dec; 51(24):7953-67. PubMed ID: 19053753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
    Tu H; Powers JP; Liu J; Ursu S; Sudom A; Yan X; Xu H; Meininger D; Degraffenreid M; He X; Jaen JC; Sun D; Labelle M; Yamamoto H; Shan B; Walker NP; Wang Z
    Bioorg Med Chem; 2008 Oct; 16(19):8922-31. PubMed ID: 18789704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel 11β-HSD1 inhibitors: C-1 versus C-2 substitution and effect of the introduction of an oxygen atom in the adamantane scaffold.
    Leiva R; Seira C; McBride A; Binnie M; Luque FJ; Bidon-Chanal A; Webster SP; Vázquez S
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4250-3. PubMed ID: 26306982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of 1,4-diaryl-1,4-dihydropyrazines as novel 11β-HSD1 inhibitors.
    Duan X; Xin H; Yan H
    Biol Pharm Bull; 2014; 37(5):840-6. PubMed ID: 24790006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
    Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.